A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters). B Animal ...

The prescribing of antiviral drugs for US children and adolescents receiving treatment for influenza was less than 60% in the ...

TLRs recognize pathogen- and danger-associated molecular patterns and activate downstream signaling cascades in order to induce proinflammatory cytokines and antiviral type I interferon by NF-κB ...

There was also a 65% relative reduction in COVID-related medical visits (95% CI 24.4-83.8) with nirmatrelvir-ritonavir versus ...

All-cause mortality risk did not significantly differ by HIV coinfection status in patients with chronic hepatitis C infection and advanced liver fibrosis who achieved sustained virologic response ...

Business which accounts for close to one-third of group sales also took in €437m in dividends from subsidiaries dotted ...

SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30 ...

COVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, ...

Presentation of Strong Preclinical Dataset: On September 25, 2024, HOOKIPA presented the preclinical proof-of-concept dataset ...

Q3 2024 Earnings Call Transcript November 9, 2024 Operator: Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call.

TFF said in September that it would work with Emory University and the Biomedical Advanced Research and Development Authority on potential use of the company's Thin Film Freezing technology for ...